The 2023 AABB guidelines overall favor a restrictive transfusion strategy, recommending RBC transfusion for hemoglobin <7 ...

The world of health devices and therapy is evolving faster than ever and 2024 is shaping up to be a groundbreaking year From wearable tech that monitors your vitals in real time to cutting-edge therap ...

Sotagliflozin, a dual SGLT1/2 inhibitor, increased hemoglobin levels in patients with type 2 diabetes and chronic kidney ...

Crohn’s disease may be a lifelong condition, but today, there are an abundance of effective treatments that can help bring relief to your symptoms and reduce your risk of experiencing more serious ...

AKI - the other main type of kidney disease - can be caused by dehydration, blood loss, urinary tract obstructions such as ...

The following is a summary of “Erythrocyte indices and response to hypoxia-inducible factor prolyl hydroxylase inhibitors in ...

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ...

Treatment involves addressing ... or folate increases your risk of many health problems, including: Pregnancy complications. Neural Tube Defects Nervous system disorders. Gastric cancer. Pernicious ...

While anemia impacts nearly a quarter of the world's population ... marked by an inability to utilize stored iron due to ...

The global anemia treatment market is on a steady growth path, with sales expected to exceed USD 10.0 billion in 2022.

Patients with symptomatic anemia associated with chronic kidney disease who are on chronic maintenance dialysis can now also ...

FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics ...